Advice
NICE is unable to make a recommendation about the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia. This is because Lilly has confirmed that it does not intend to make an evidence submission for the appraisal. They consider that there is not enough evidence to provide an evidence submission.
Information
If NHS organisations wish to consider tadalafil for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position if the company decides that it wants to make an evidence submission.
ISBN: 978-1-4731-6738-4